News | May 07, 2026
Neuland Labs and LIR Life partner on next-gen transdermal GLP-1 obesity therapy platform
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Keeps Halo Pharma to drive independent growth
Healthcare and consumer wellness leader brings extensive experience in business transformation, commercial strategy and growth leadership to Fertin India
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Subscribe To Our Newsletter & Stay Updated
